Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Combination Treatment with TBI-1401(HF10), a Replication-competent HSV-1 Oncolytic Virus, and Ipilimumab in Japanese Patients with Stage IIIB, IIIC, or IV Unresectable or Metastatic Malignant Melanoma

NCT03153085 is registered in ClinicalTrials.gov with Takara Bio Inc. as lead sponsor.

NCT NCT03153085
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03153085 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Combination Treatment with TBI-1401(HF10), a Replication-competent HSV-1 Oncolytic Virus, and Ipilimumab in Japanese Patients with Stage IIIB, IIIC, or IV Unresectable or Metastatic Malignant Melanoma
Lead sponsor
Takara Bio Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 25, 2017
Completion date
December 14, 2018
Enrollment
28 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma stage iii, melanoma stage iv